Market Analysis and Price Projections for NDC 68462-0943: Travoprost Ophthalmic Solution
Overview of NDC 68462-0943
NDC 68462-0943 corresponds to Travoprost Ophthalmic Solution, a medication manufactured and labeled by Glenmark Pharmaceuticals Inc., USA. This product is used primarily for the treatment of glaucoma and ocular hypertension by reducing intraocular pressure.
Market Context
Pharmaceutical Industry Trends
The pharmaceutical industry is undergoing significant transformations driven by digital innovation, regulatory changes, and market dynamics. Pricing and access to drugs are among the top concerns for life sciences executives, with nearly half expecting these factors to significantly impact their strategies in 2025[3].
Generic and Biosimilar Competition
Generic drugs, including ophthalmic solutions like Travoprost, face increasing competition from biosimilars and other generic versions. This competition can lead to price pressures, as seen in the broader market where generic drugs have experienced median price increases of 19.9% in recent years[2].
Pricing Factors
Regulatory Oversight and Transparency
Prescription drug pricing is heavily influenced by regulatory oversight and transparency initiatives. Programs like Oregon's Drug Price Transparency Program require manufacturers to report price increases and provide reasons for these changes. Factors such as rebates, co-pay assistance programs, research and development costs, and obligations to shareholders are commonly cited reasons for price increases[2][4].
Supply Chain Dynamics
The price of a prescription drug, including ophthalmic solutions, is affected by interactions and financial negotiations within the pharmaceutical supply chain. Entities such as pharmacy benefit managers (PBMs), health insurers, and manufacturers all play roles in determining the final cost to consumers[2][4].
Current Pricing
Historical Context
While specific historical pricing data for NDC 68462-0943 is not provided, the broader trend for generic drugs indicates that prices can fluctuate significantly. For example, a generic version of naproxen saw a 2,527% price increase from 2012 to 2021, highlighting the potential for dramatic price changes in the generic drug market[2].
Comparative Pricing
Travoprost Ophthalmic Solution, as a generic product, is generally priced lower than its brand-name counterparts. However, prices can vary based on market competition, the number of competitors, and the drug's efficacy and profitability.
Price Projections
Short-Term Projections
In the short term, prices for Travoprost Ophthalmic Solution are likely to remain stable or experience moderate increases, aligning with the median price increase of 19.9% observed for generic drugs. This stability is influenced by the competitive nature of the generic drug market and regulatory oversight aimed at transparency and accountability[2].
Long-Term Projections
Long-term price projections may be influenced by several factors:
- Competition from New Generics: As more generic versions of Travoprost enter the market, competition is likely to increase, potentially driving prices down.
- Regulatory Changes: Continued emphasis on transparency and potential implementation of upper payment limits could further regulate price increases[2][4].
- Market Dynamics: The overall demand for glaucoma treatments and the introduction of new therapies could impact pricing strategies.
Key Takeaways
- Regulatory Influence: Pricing for Travoprost Ophthalmic Solution is heavily influenced by regulatory transparency programs and supply chain dynamics.
- Market Competition: The generic drug market, including ophthalmic solutions, is highly competitive, which can lead to price stability or moderate increases.
- Long-Term Trends: Long-term prices may be affected by increased competition, regulatory changes, and market demand.
FAQs
-
What is NDC 68462-0943 used for?
- NDC 68462-0943 corresponds to Travoprost Ophthalmic Solution, used to treat glaucoma and ocular hypertension by reducing intraocular pressure.
-
Who manufactures NDC 68462-0943?
- Glenmark Pharmaceuticals Inc., USA, manufactures and labels this product.
-
What factors influence the price of Travoprost Ophthalmic Solution?
- Factors include rebates, co-pay assistance programs, research and development costs, obligations to shareholders, and supply chain dynamics.
-
How does regulatory oversight impact pricing?
- Regulatory programs like Oregon's Drug Price Transparency Program require manufacturers to report price increases and provide reasons, promoting transparency and accountability.
-
What are the long-term price projections for Travoprost Ophthalmic Solution?
- Long-term prices may be influenced by increased competition from new generics, regulatory changes, and market demand, potentially leading to stable or slightly decreased prices.
Sources
- FDA Report: NDC 68462-438 Oral Tablet, Film Coated Olmesartan Medoxomil.
- Oregon Drug Price Transparency Program: Prescription Drug Price Transparency Results and Recommendations.
- Deloitte Insights: 2025 life sciences outlook.
- Oregon Drug Price Transparency Program: Prescription Drug Price Transparency Results and Recommendations (2019).
- FindACode: GLENMARK PHARMACEUTICALS INC - NDC Labeler/Manufacturer.